The Biogen Foundation's STAR Initiative--for Science, Teacher support, Access and Resources--is intended to strengthen and support educational offerings in these cities by helping increase access to STEM resources and opportunities for students currently underrepresented in STEM college or career pathways.
Through a coordinated network of grantees, STAR endeavors to help low-income students develop and sustain their interest in STEM, gain necessary STEM exposure and enrichment opportunities, and successfully transition into post-secondary education in pursuit of STEM careers.
The Biogen Foundation will soon be soliciting proposals from nonprofits providing services in the areas of STEM access, exploration, and preparedness for students in grades 6-12.
Successful applicants will partner with Cambridge and/or Somerville public schools by providing in- or out-of-school STEM awareness, exploration, and skill-building support and activities.
Organizations selected to receive grants will become part of a coordinated provider network managed by the Biogen Foundation. The STAR initiative is intended to complement, supplement, and strengthen the existing STEM education landscapes in Cambridge and Somerville.
The Biogen Foundation supports access to science education and to essential human services for children and their families in the communities in which Biogen facilities are located.
The foundation is committed to sparking a passion for science and discovery, supporting effective science education initiatives, and strengthening efforts to make science education and science careers accessible to diverse populations.
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation